This statistic shows the death rate from liver cirrhosis in the U.S. in 2019, by age. According to the data, during that time the highest death rate was 37.9 per 100,000 and was among those aged 75-84 years.

In 2022, the death rate due to alcohol-related liver cirrhosis among those aged 45-54 years was 12.4 per 100,000. This statistic shows the rate of alcohol-related liver cirrhosis deaths in the U.S. in 2022, by age.

Legacy unique identifier: P00208

This statistic displays the number of alcoholic liver disease related deaths in England in 2021, by gender and age. The number of deaths from alcoholic liver disease was significantly higher among men than women. In 2021, 678 men and 401 women aged between 55 and 59 years old died from alcoholic liver disease.

This record contains raw data related to article “Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis"

Abstract

Importance: Expansion of donor acceptance criteria for liver transplant increased the risk for early allograft failure (EAF), and although EAF prediction is pivotal to optimize transplant outcomes, there is no consensus on specific EAF indicators or timing to evaluate EAF. Recently, the Liver Graft Assessment Following Transplantation (L-GrAFT) algorithm, based on aspartate transaminase, bilirubin, platelet, and international normalized ratio kinetics, was developed from a single-center database gathered from 2002 to 2015.

Objective: To develop and validate a simplified comprehensive model estimating at day 10 after liver transplant the EAF risk at day 90 (the Early Allograft Failure Simplified Estimation [EASE] score) and, secondarily, to identify early those patients with unsustainable EAF risk who are suitable for retransplant.

Design, setting, and participants: This multicenter cohort study was designed to develop a score capturing a continuum from normal graft function to nonfunction after transplant. Both parenchymal and vascular factors, which provide an indication to list for retransplant, were included among the EAF determinants. The L-GrAFT kinetic approach was adopted and modified with fewer data entries and novel variables. The population included 1609 patients in Italy for the derivation set and 538 patients in the UK for the validation set; all were patients who underwent transplant in 2016 and 2017.

Main outcomes and measures: Early allograft failure was defined as graft failure (codified by retransplant or death) for any reason within 90 days after transplant.

Results: At day 90 after transplant, the incidence of EAF was 110 of 1609 patients (6.8%) in the derivation set and 41 of 538 patients (7.6%) in the external validation set. Median (interquartile range) ages were 57 (51-62) years in the derivation data set and 56 (49-62) years in the validation data set. The EASE score was developed through 17 entries derived from 8 variables, including the Model for End-stage Liver Disease score, blood transfusion, early thrombosis of hepatic vessels, and kinetic parameters of transaminases, platelet count, and bilirubin. Donor parameters (age, donation after cardiac death, and machine perfusion) were not associated with EAF risk. Results were adjusted for transplant center volume. In receiver operating characteristic curve analyses, the EASE score outperformed L-GrAFT, Model for Early Allograft Function, Early Allograft Dysfunction, Eurotransplant Donor Risk Index, donor age × Model for End-stage Liver Disease, and Donor Risk Index scores, estimating day 90 EAF in 87% (95% CI, 83%-91%) of cases in both the derivation data set and the internal validation data set. Patients could be stratified in 5 classes, with those in the highest class exhibiting unsustainable EAF risk.

Conclusions and relevance: This study found that the developed EASE score reliably estimated EAF risk. Knowledge of contributing factors may help clinicians to mitigate risk factors and guide them through the challenging clinical decision to allocate patients to early liver retransplant. The EASE score may be used in translational research across transplant centers.

Abstract Background: Recently, a new HF entity, with LVEF between 40-49%, was presented to comprehend and seek better therapy for HF with preserved LVEF (HFpEF) and borderline, in the means that HF with reduced LVEF (HFrEF) already has well-defined therapy in the literature. Objective: To compare the clinical-therapeutic profile of patients with HF with mid-range LVEF (HFmrEF) with HFpEF and HFrEF and to verify predictors of hospital mortality. Method: Historical cohort of patients admitted with decompensated HF at a supplementary hospital in Recife/PE between April/2007 - August/2017, stratified by LVEF (< 40%/40 - 49/≥ 50%), based on the guideline of the European Society of Cardiology (ESC) 2016. The groups were compared and Logistic Regression was used to identify predictors of independent risk for in-hospital death. Results: A sample of 493 patients, most with HFrEF (43%), HFpEF (30%) and HFmrEF (26%). Average age of 73 (± 14) years, 59% men. Hospital mortality 14%, readmission within 30 days 19%. In therapeutics, it presented statistical significance among the 3 groups, spironolactone, in HFrEF patients. Hospital death and readmission within 30 days did not make difference. In the HFmrEF group, factors independently associated with death were: valve disease (OR: 4.17, CI: 1.01-9.13), altered urea at admission (OR: 6.18, CI: 1.78-11.45) and beta-blocker hospitalization (OR: 0.29, CI: 0.08-0.97). In HFrEF, predictors were: prior renal disease (OR: 2.84, CI: 1.19-6.79), beta-blocker at admission (OR: 0.29, CI: 0.12-0.72) and ACEI/ ARB (OR: 0.21, CI: 0.09-0.49). In HFpEF, only valve disease (OR: 4.61, CI: 1.33-15.96) and kidney disease (OR: 5.18, CI: 1.68-11.98) were relevant. Conclusion: In general, HFmrEF presented intermediate characteristics between HFrEF and HFpEF. Independent predictors of mortality may support risk stratification and management of this group.

Plus-minus values are means ± standard deviations. The denominator used to calculate the percentage of infants with a specific outcome was the number of infants randomly assigned to each treatment group for whom that outcome was known at 18 to 24 months. This number was the total number in each group, unless otherwise specified. The motor and cognitive scores were assessed with the BSID III (scores range from 50 to 150, where 150 indicates most advanced development).The relative risk of each outcome was calculated for the BA ratio group as compared to the TSB group. In the B/A ratio group the mean (±SD) age at death was 30±16 days and 10±7 days in the TSB group. Severe NDI was a composite motor score of

China COVID-19: Number of Death(From 12/8/2022): Respiratory Failure Caused by COVID-19: To-Date data was reported at 6,473.000 Person in 26 Jan 2023. This records an increase from the previous number of 6,184.000 Person for 19 Jan 2023. China COVID-19: Number of Death(From 12/8/2022): Respiratory Failure Caused by COVID-19: To-Date data is updated daily, averaging 6,184.000 Person from Jan 2023 (Median) to 26 Jan 2023, with 3 observations. The data reached an all-time high of 6,473.000 Person in 26 Jan 2023 and a record low of 5,503.000 Person in 12 Jan 2023. China COVID-19: Number of Death(From 12/8/2022): Respiratory Failure Caused by COVID-19: To-Date data remains active status in CEIC and is reported by Chinese Center for Disease Control and Prevention. The data is categorized under China Premium Database’s Socio-Demographic – Table CN.GZ: COVID-19: No of Death.

ObjectiveWe sought to develop and validate a mortality prediction model for heart transplantation (HT) using nutrition-related indicators, which clinicians could use to identify patients at high risk of death after HT.MethodThe model was developed for and validated in adult participants in China who received HT between 1 January 2015 and 31 December 2020. 428 subjects were enrolled in the study and randomly divided into derivation and validation cohorts at a ratio of 7:3. The likelihood-ratio test based on Akaike information was used to select indicators and develop the prediction model. The performance of models was assessed and validated by area under the curve (AUC), C-index, calibration curves, net reclassification index, and integrated discrimination improvement.ResultThe mean (SD) age was 48.67 (12.33) years and mean (SD) nutritional risk index (NRI) was 100.47 (11.89) in the derivation cohort. Mortality after HT developed in 66 of 299 patients in the derivation cohort and 28 of 129 in the validation cohort. Age, NRI, serum creatine, and triglyceride were included in the full model. The AUC of this model was 0.76 and the C statistics was 0.72 (95% CI, 0.67–0.78) in the derivation cohort and 0.71 (95% CI, 0.62–0.81) in the validation cohort. The multivariable model improved integrated discrimination compared with the reduced model that included age and NRI (6.9%; 95% CI, 1.8%–15.1%) and the model which only included variable NRI (14.7%; 95% CI, 7.4%–26.2%) in the derivation cohort. Compared with the model that only included variable NRI, the full model improved categorical net reclassification index both in the derivation cohort (41.8%; 95% CI, 9.9%–58.8%) and validation cohort (60.7%; 95% CI, 9.0%–100.5%).ConclusionThe proposed model was able to predict mortality after HT and estimate individualized risk of postoperative death. Clinicians could use this model to identify patients at high risk of postoperative death before HT surgery, which would help with targeted preventative therapy to reduce the mortality risk.

Between 1970 and 1988, major cardiovascular diseases were the most common cause of death in both the United States and Soviet Union. However, the death rate in the U.S. fell between the given years, whereas the USSR's rate increased significantly, especially during the 1970s. Malignancies (i.e. cancers) were the second most common cause of death, with both death rates rising over time. Other causes that that varied greatly between the two countries were accidents and adverse effects, where the USSR's rate was almost double that of the U.S. in 1980; pulmonary diseases, where the U.S. rate was higher in 1988 despite having been four times lower in 1970; and diabetes, where the U.S. rate was higher by a factor of 11 in 1970 and a factor of four in 1988.

There were, of course, variations between the two countries in their standards of diagnosis and the classification of causes of death, with U.S. records generally thought to be more accurate, whereas the USSR's rates improved with time. The Soviet Union also did not provide separate data for deaths caused by liver disease or pneumonia/influenza, possibly due to the rise and prevalence of alcohol-related deaths during the given period, which the government wished to downplay. Preventable deaths related to alcohol and substance abuse (including tobacco) were major factors in the Soviet Union's high death rates in certain categories, such as accidental deaths, pulmonary disease, and suicides. In contrast, the U.S.' higher rate of diabetes deaths has been attribute to an increase in levels of Type 2 diabetes, which is most-commonly caused by lifestyle and dietary factors.

In 2023, California had the highest number of liver transplants performed among all U.S. states. That year, there were around 1,200 liver transplants performed in California. The state with the second highest number of liver transplants was Texas. Liver transplants are the second most common transplant in the United States, behind kidney transplants. Liver transplants in the United States In 2022, there were just over 9,500 liver transplants carried out in the United States. Most liver transplants in the U.S. are among adults aged 50 to 64 years, with this age group accounting for around 45 percent of all liver transplants in 2023. The current need for liver transplants exceeds availability, with over 10 thousand people in the United States waiting to receive a liver transplant. Liver transplantation is a treatment option for those suffering from end-stage chronic liver disease, in which the liver is damaged beyond repair. Liver disease End-stage chronic liver disease, or liver failure, has various causes including cirrhosis, hepatitis B and C, and liver cancer. Around half of all deaths in the United States caused by liver cirrhosis are related to alcohol use. Liver cirrhosis is scarring of the liver because of long-term damage. The death rate due to alcohol-related cirrhosis in the United States has increased over the past couple decades. Men are much more likely to die from liver cirrhosis than women.

ObjectiveTo determine the long-term survival of patients receiving home hemodialysis (HHD) through self-punctured arteriovenous access.MethodsWe conducted an observational study of all patients receiving HHD at our facility between 2001 and 2020. The primary outcome was treatment survival, and it was defined as the duration from HHD initiation to the first event of death or technique failure. The secondary outcomes were the cumulative incidence of technique failure and mortality. Cox proportional hazard models were used to identify the predictive factors for treatment survival.ResultsA total of 77 patients (mean age, 50.7 years; 84.4% male; 23.4% with diabetes) were included. The median dialysis duration was 18 hours per week, and all patients self-punctured their arteriovenous fistula. During a median follow-up of 116 months, 30 treatment failures (11 deaths and 19 technique failures) were observed. The treatment survival was 100% at 1 year, 83.5% at 5 years, 67.2% at 10 years, and 34.6% at 15 years. Age (adjusted hazard ratio [aHR], 1.07) and diabetes (aHR, 2.45) were significantly associated with treatment survival. Cardiovascular disease was the leading cause of death, and vascular access-related issues were the primary causes of technique failure, which occurred predominantly after 100 months from HHD initiation.ConclusionThis study showed a favorable long-term prognosis of patients receiving HHD. HHD can be a sustainable form of long-term kidney replacement therapy. However, access-related technique failures occur more frequently in patients receiving it over the long term. Therefore, careful management of vascular access is crucial to enhance technique survival.

BackgroundHigh body mass index increases the risk of heart failure morbidity and mortality. It is unclear whether a high body mass index is associated with prognosis in patients with heart failure with mildly reduced left ventricular ejection fraction (HFmrEF). We retrospectively analyzed the effect of a high body mass index on the prognosis of patients with HFmrEF.MethodsWe investigated the association between body mass index and cardiovascular death (death from any cardiovascular mechanism) in 1,691 HFmrEF patients (mean age, 68 years; 35% female) in Xiangtan Central Hospital. Using Cox proportional hazards models, body mass index was assessed as a continuous and a categorical variable.ResultsCardiovascular death occurred in 133 patients (82 males and 51 females) after 1 year of follow-up. After adjustment for established risk factors, there was a 7.5% increase in the risk of cardiovascular death for females for each increment of 1 in BMI. In contrast, changes in male body mass index were not significantly associated with cardiovascular death (P = 0.097). Obese subjects had a 1.8-fold increased risk of cardiovascular death compared with subjects with a normal body mass index. The hazard ratio for females was 2.163 (95% confidence interval: 1.150–4.066). Obesity was not significantly associated with cardiovascular death in males (P = 0.085).ConclusionAn increased body mass index is associated with an increased risk of cardiovascular death in patients with HFmrEF; however, this risk was mainly associated with female patients with HFmrEF and less with male patients with HFmrEF.

The leading causes of death among the white population of the United States are cardiovascular diseases and cancer. Cardiovascular diseases and cancer accounted for a combined 40.9 percent of all deaths among this population in 2022. In 2020 and 2021, COVID-19 was the third leading cause of death among white people. Disparities in causes of death In the United States, there exist disparities in the leading causes of death based on race and ethnicity. For example, chronic liver disease and cirrhosis is the tenth leading cause of death among the white population and the eighth among the Hispanic population, but is not among the ten leading causes for Black people. On the other hand, homicide is the seventh leading cause of death among the Black population, but is not among the 10 leading causes for whites or Hispanics. However, cardiovascular diseases and cancer by far account for the highest share of deaths for every race and ethnicity. Diseases of despair The American Indian and Alaska Native population in the United States has the highest rates of death from suicide, drug overdose, and alcohol. Together, these three behavior-related conditions are often referred to as diseases of despair. Asians have by far the lowest rates of death due to drug overdose and alcohol, as well as slightly lower rates of suicide.

Mortality from chronic renal failure (ICD-10 N18 equivalent to ICD-9 585). To reduce deaths from chronic renal failure. Indicator currently under review. Legacy unique identifier: P00216

The number of deaths caused by heart disease has decreased in the United States from 321.8 per 100,000 population in 1990 to 161.5 deaths per 100,000 population in 2019. Nevertheless, heart disease is still the leading cause of death in the country, followed closely by cancer, which has a mortality rate of 146.2 per 100,000 people.

Heart disease in the U.S.

Diseases of the heart and blood vessels are often associated with atherosclerosis which occurs when plaque builds up along arterial walls. This can limit the flow of blood and can lead to blood clots, a common cause of stroke or heart attacks. Other types of heart disease include arrhythmia (abnormal heart rhythms) and heart valve problems. Many of these diseases can be treated with medication, although many complications will still remain. One of the leading cholesterol lowering drugs in the United States, Crestor, generated around 1.2 billion U.S. dollars of revenue in 2021.

Risk Factors for heart disease There are many risk factors associated with the development of heart disease including family history, ethnicity, and age. However, there are other factors that can be modified through lifestyle changes such as physical inactivity, smoking, and unhealthy diets. Obesity has also been commonly associated with risk factors like hypertension and diabetes type II. In the U.S., some 30 percent of white adults are currently obese.

Years of life lost due to mortality from chronic renal failure (ICD-10 N18). Years of life lost (YLL) is a measure of premature mortality. Its primary purpose is to compare the relative importance of different causes of premature death within a particular population and it can therefore be used by health planners to define priorities for the prevention of such deaths. It can also be used to compare the premature mortality experience of different populations for a particular cause of death. The concept of years of life lost is to estimate the length of time a person would have lived had they not died prematurely. By inherently including the age at which the death occurs, rather than just the fact of its occurrence, the calculation is an attempt to better quantify the burden, or impact, on society from the specified cause of mortality. Legacy unique identifier: P00328

BackgroundHemophagocytic lymphocytosis (HLH) is a rare life-threatening hyperinflammatory syndrome in which early mortality remains high in patients with HLH.MethodsWe retrospectively collected the medical records of all pediatric patients diagnosed with HLH at the West China Second Hospital of Sichuan University between January 2014 and December 2020. Collect demographic, laboratory, clinical, genetic profiles, treatment information and perform statistical analysis from records. Risk factors for death 30 days after admission were evaluated using a multivariable logistic regression model.ResultsA total of 110 pediatric HLH patients were enrolled. The median age of patients was 44 months (IQR 23-100.5) and 62 (56.4%) in males. The 30-day mortality rate for admission to this cohort was 34 (30.9%). Multivariate logistic regression analysis showed that heart failure (OR = 13.389, 95% CI, 1.671–107.256, p = 0.015) and hypoproteinemia (OR = 4.841, 95% CI, 1.282–18.288, p = 0.020) were associated with increased early mortality in children with HLH.ConclusionsThese identified risk factors may help clinicians stratify patients with HLH and develop targeted treatment strategies. More research is needed to explore the best treatment strategies for patients with HLH to reduce early mortality in patients with HLH.

BackgroundSpecialist palliative care teams are consulted during hospital admission for advice on complex palliative care. These consultations need to be timely to prevent symptom burden and maintain quality of life. Insight into specialist palliative care teams may help improve the outcomes of palliative care.MethodsIn this retrospective observational study, we analyzed qualitative and quantitative data of palliative care consultations in a six-month period (2017 or 2018) in four general hospitals in the northwestern part of the Netherlands. Data were obtained from electronic medical records.ResultsWe extracted data from 336 consultations. The most common diagnoses were cancer (54.8%) and organ failure (26.8%). The estimated life expectancy was less than three months for 52.3% of all patients. Within two weeks after consultation, 53.2% of the patients died, and the median time until death was 11 days (range 191) after consultation. Most patients died in hospital (49.4%) but only 7.5% preferred to die in hospital. Consultations were mostly requested for advance care planning (31.6%). End-of-life preferences focused on last wishes and maintaining quality of life.ConclusionThis study provides detailed insight into consultations of palliative care teams and shows that even though most palliative care consultations were requested for advance care planning, consultations focus on end-of-life care and are more crisis-oriented than prevention-oriented. Death often occurs too quickly after consultation for end-of-life preferences to be met and these preferences tend to focus on dying. Educating healthcare professionals on when to initiate advance care planning would promote a more prevention-oriented approach. Defining factors that indicate the need for timely palliative care team consultation and advance care planning could help timely identification and consultation.